Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.10.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Consolidated Statements Of Operations    
Revenues
Operating expenses:    
General and administrative 313,094 396,143
Total operating expenses 313,094 396,143
Loss from operations (313,094) (396,143)
Other income (expense):    
Loss on fair value adjustment - derivatives (12,023)
Interest expense (317,194) (218,339)
Interest expense - beneficial conversion feature 15,250
Total other income (expense) (329,217) (203,089)
Loss before provision for income taxes (642,311) (599,232)
Provision for income tax
Net loss (642,311) (599,232)
Less: Net loss attributable to noncontrolling interest 3,226 4,102
Net loss attributable to TranBioTec, Inc. $ (639,085) $ (595,130)
Net loss per share    
(Basic and fully diluted) $ (0.007) $ (0.009)
Weighted average number of common shares outstanding 97,823,538 67,320,740